Details for New Drug Application (NDA): 218426
✉ Email this page to a colleague
NDA 218426 describes DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, which is a drug marketed by Actavis Elizabeth and Hetero Labs Ltd Iii and is included in two NDAs. Additional details are available on the DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE profile page.
The generic ingredient in DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is dextromethorphan hydrobromide; quinidine sulfate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dextromethorphan hydrobromide; quinidine sulfate profile page.
The generic ingredient in DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is dextromethorphan hydrobromide; quinidine sulfate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dextromethorphan hydrobromide; quinidine sulfate profile page.
Summary for 218426
| Tradename: | DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE |
| Applicant: | Hetero Labs Ltd Iii |
| Ingredient: | dextromethorphan hydrobromide; quinidine sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 20MG;10MG | ||||
| Approval Date: | Aug 28, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
